comparemela.com

Latest Breaking News On - Control workflow - Page 1 : comparemela.com

Medtronic receives FDA approval for SynchroMed III system

Medtronic has received U.S. Food and Drug Administration (FDA) approval of its next-generation SynchroMed III intrathecal drug delivery system for patients with chronic pain, cancer pain, and severe spasticity. SynchroMed III is a targeted drug delivery (TDD) platform that alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord. SynchroMed III is an upgraded system compared to the SynchroMed II system, featuring a new "refill only" physician workflow for more efficient programming, improved electronics with firmware capable of being updated after implant, and additional protections for patient data through enhanced cybersecurity. The system also carries forward several mid-generation durable design enhancements from the SynchroMed II pump which have contributed to the long-term safety and reliability of the device. TDD therapy is a safe, proven, and effective way to manage chronic pain, cancer pain or severe spasticity with greater effi

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.